Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility

Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company today announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Monroe, North Carolina (USA) with a Voluntary Action Indicated (VAI) status.

The inspection was conducted at the Company's manufacturing facility from 09 June to 17 June 2025.

With this positive development, the Company will restart commercial manufacturing at the Monroe site.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1920.95 as compared to the previous close of Rs. 1881.45. The total number of shares traded during the day was 17489 in over 1577 trades.

The stock hit an intraday high of Rs. 1927.10 and intraday low of 1875.65. The net turnover during the day was Rs. 33366431.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA IER MonroeFacility